Zora Biosciences is a company headquartered in Finland. Brouky records 1 investor associated with the company.
Zora Biosciences is a Finland-based diagnostic company that uses mass spectrometry to identify lipid biomarkers and develop high-throughput clinical tests for cardiometabolic diseases, including the CERT2 ceramide-based cardiovascular risk score and the dSCORE for type 2 diabetes. Tests are commercialized with international partners and via the company's reference laboratory in Finland.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.